Tango Therapeutics

Tango Therapeutics, Inc. operates as a biotechnology company, which engages in discovering and delivering precision cancer medicines. Its primary program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Cambridge, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida. Abstract titles, presentation information and text, if provided by the meeting organizers, are currently available on the AACR 2023 Annual Meeting website.

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

BOSTON, March 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported that it is aware of the current situation affecting Silicon Valley Bank (SVB), it is monitoring this situation closely and does not expect its exposure to SVB will require any change to its previously provided guidance that it has sufficient cash, cash equivalents and marketable securities to fund operations into 2025.

Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank

NEW YORK--(BUSINESS WIRE)---- $TNGX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BCTG Acquisition Corp., which merged with Tango Therapeutics, Inc. ("Tango" or "the Company") (NASDAQ: TNGX) on August 10, 2021. Such investors who continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/tngx.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Tango Therapeutics, Inc (TNGX) Investigation

Tango Therapeutics' SPAC entry to the market and Gilead deal has put a large dollar figure besides its name. Tango has an upcoming proof of concept data readout that should validate its platform.

Tango Therapeutics: Upcoming Proof Of Concept Data Is A Major Catalyst

TNG908 granted Orphan Drug Designation in U.S. for the treatment of malignant glioma TNG908 granted Orphan Drug Designation in U.S. for the treatment of malignant glioma

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates

Shares of early clinical-stage biotech Tango Therapeutics, Inc. are down ~50% since going public in August 2021 – primarily victimized by a lack of catalysts and a tough market. However, the shares have rallied strongly over the past month.

Tango Therapeutics: Behind The Recent Momentum

– Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France –

Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights

ACM Research

Akouos

Biohaven Pharmaceutical Hld

Cano Health

FingerMotion

Immunovant Inc

Ngm Biopharmaceuticals Inc

Nutex Health Inc

TuSimple Holdings

Small-cap stocks can offer big returns in a short period of time, especially when the economy is rebounding from a slowdown.

These Were the Five Best and Worst Performing Small-cap Stocks in October 2022

Tango Therapeutics, Inc. (TNGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

The clinical-stage biotech company has two candidates in its drug pipeline.

Why Tango Therapeutics Shares Rose 39.7% This Week

BOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that three abstracts have been selected for presentation as posters at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held in Barcelona, Spain from October 26-28, 2022.

Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Tango Therapeutics, Inc. (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Tango Therapeutics, Inc. (TNGX) Stock Jumps 16.3%: Will It Continue to Soar?

Applied Therapeutics Inc

Douglas Elliman

Best penny stocks to buy this week according to insiders. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 3 With Heavy Insider Trading In October

TNG260 is in preclinical development as a first-in-class CoREST deacetylase inhibitor for the treatment of STK11-mutant cancers TNG260 is in preclinical development as a first-in-class CoREST deacetylase inhibitor for the treatment of STK11-mutant cancers

Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will be available on-demand starting on Monday, September 12, 2022 at 7:00 AM ET.

Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 219.4% in Tango Therapeutics, Inc. (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Tango Therapeutics, Inc. (TNGX) Climb 219% to Reach the Level Wall Street Analysts Expect?

– Patients with MTAP-deleted solid tumors being actively enrolled in ongoing Phase 1/2 trial of TNG908, an MTA-cooperative PRMT5 inhibitor –

Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the company was added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes, effective after the U.S. market closed on June 24, 2022, as part of the 2022 Russell indexes annual reconstitution.

Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

– Phase 1/2 trial of TNG908, a synthetic lethal PRMT5 inhibitor, for the treatment of MTAP-deleted solid tumors open for enrollment –

Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

The average of price targets set by Wall Street analysts indicates a potential upside of 176.2% in Tango Therapeutics, Inc. (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 176% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should Know

- TNG908 receives Fast Track designation, expects Phase 1/2 trial to start in 2Q 2022 -

Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that three abstracts have been selected for presentation as posters at the American Association for Cancer Research (AACR) 2022 Annual Meeting, taking place from April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and online.

Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the presentation of an e-Poster at the 2022 European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Congress, which is being held virtually from March 7 – 8, 2022.

Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies Congress

The FDA has cleared Tango Therapeutics Inc's (NASDAQ: TNGX) Investigational New Drug (IND) application for its lead program, TNG908. TNG908 is a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to kill cancer cells with a methylthioadenosine phosphorylase (MTAP) deletion.

Tango Therapeutics' TNG908 IND For Cancer Study Gets Green Signal By FDA

- TNG908 IND cleared by FDA, Phase 1/2 trial expected to start in 1H 2022

News for Tango Therapeutics Stock (TNGX)